Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash from Financing Activities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Cash from Financing Activities for 4 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 7251.04% to $44.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.5 million through Dec 2025, up 2780.7% year-over-year, with the annual reading at $43.5 million for FY2025, 2780.7% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $44.7 million at Spruce Biosciences, up from -$402000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $50.5 million in Q1 2023, with the low at -$625000.0 in Q4 2024.
  • Average Cash from Financing Activities over 4 years is $5.7 million, with a median of -$382500.0 recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 57519.32% in 2023, while the deepest fall reached 1633.33% in 2023.
  • Over 4 years, Cash from Financing Activities stood at $36000.0 in 2022, then plummeted by 1633.33% to -$552000.0 in 2023, then dropped by 13.22% to -$625000.0 in 2024, then soared by 7251.04% to $44.7 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $44.7 million, -$402000.0, and -$400000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.